BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Working to Deliver Novel Treatment for Chronic Pain Sufferers

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, recently announced a new research and development agreement to create a time-release ketamine implant to treat fibromyalgia and other chronic pain conditions. Silo intends to leverage its existing partnerships with academic research institutions to help move the novel treatment for chronic pain sufferers through the Food and Drug Administration’s approval process as efficiently as possible. The fibromyalgia market grew to $3.1 billion last year and is expected to continue increasing at a compound annual growth rate of 4% over the next decade. Meanwhile, the larger chronic pain market is projected to exceed $140 billion by 2030, with many chronic pain sufferers in desperate need of a treatment that delivers powerful relief without the serious side effects or risk of addiction that come with opioids.

To view the full press release, visit https://ibn.fm/FbksG

About Silo Pharma Inc.

Silo Pharma is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which it believes will be transformative to the well-being of patients and the health care industry. For more information about the company, visit www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW
Breaks Categories: News

Recent Posts

BioMedNewsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Reports Fiscal Q2 2027 Financial Results, Highlights Phase 3 Pipeline Progress

This article has been disseminated on behalf of Helus Pharma and may include paid advertising.…

5 hours ago

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Reports $12.22 Million in Cash and Digital Assets, Advances Lucid-MS Phase 2 Trial

Quantum BioPharma (NASDAQ: QNTM) reported unaudited financial and operational results for the third quarter ended…

3 days ago

BioMedNewsBreaks – Earth Science Tech Inc. (ETST) Leverages Vertically Integrated Business Model to Drive Growth and Profitability

Earth Science Tech (OTCQB: ETST) is leveraging its diversified conglomerate business model to build a…

4 days ago

BioMedNewsBreaks – Adaptogenics Health Corp. (CSE: ADPT) Positions for Emerging Peptide Market with Focus on Quality, Traceability

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. Adaptogenics (CSE: ADPT)…

4 days ago

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Reports Shareholder Meeting Results, Closes Private Placement Increasing Insider Voting Control

Quantum BioPharma (NASDAQ: QNTM) announced the results of its Nov. 10, 2026, annual general and…

5 days ago